The American Cancer Society reports a 3% annual increase in prostate cancer cases, emphasizing that early screening is critical for improving survival and treatment outcomes.

The American Cancer Society (ACS) projects 333,830 new prostate cancer cases in the United States for 2026, with 36,320 deaths expected. Data from the ACS Cancer Statistics 2026 report indicates that cases rose by approximately 3% annually between 2014 and 2022, with the most significant growth occurring in advanced-stage diagnoses.

Drivers of Rising Diagnoses

The ACS attributes the rise in diagnoses primarily to an increase in the number of men undergoing screening. However, Dr. William Dahut, chief scientific officer at the ACS, noted that a growing proportion of these cases are being identified at advanced stages. This suggests that for many men, particularly those at high risk, discussions regarding screening are occurring too late.

Benefits of Early Detection

Early detection remains the primary goal of screening, as localized prostate cancer—cancer that has not spread beyond the gland—has a nearly 100% five-year survival rate. When detected early, patients often have access to a broader range of treatment options, including active surveillance, surgery, and radiation therapy. These interventions can be less aggressive, potentially preserving urinary function and sexual health.

Screening and Diagnostic Procedures

In the U.S., screening decisions are based on individual consultations between patients and healthcare professionals. The Prostate-Specific Antigen (PSA) blood test serves as a primary indicator; while elevated levels do not confirm cancer, they signal the need for further investigation. If results are abnormal, doctors may order additional procedures, such as a digital rectal exam, MRI imaging, or a biopsy.